SequelSEC

Allarity Therapeutics, Inc. ALLR

Pharmaceutical Preparations · CIK 0001860657 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2026-06-30
Operating income
-$2.67M
Fiscal year ended 2026-06-30
Free cash flow
-$2.56M
Fiscal year ended 2026-06-30

Allarity Therapeutics, Inc. (ALLR) reported revenue of $0 and net income of -$3.40M for the fiscal year ended 2026-06-30. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from Allarity Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Allarity Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-06-302025-03-312024-12-31
Revenue$0$25.00K$320.00K$0$0Unavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$2.67M-$2.69M-$5.44M-$4.13M-$3.04MUnavailable
Net income-$3.40M-$2.75M-$6.18M-$2.32M-$2.73MUnavailable
Research & development$1.34M$1.30M$2.88M$2.32M$1.40MUnavailable
Weighted-average diluted sharesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax incomeUnavailableUnavailable-$6.18M-$2.32M-$2.73MUnavailable
Income tax expenseUnavailableUnavailable$0$0$0Unavailable
Diluted EPSUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$1.33M$1.42M$2.88M$1.81M$1.63MUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Allarity Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-06-302025-03-312024-12-31
Cash & equivalents$16.98M$19.81M$14.69M$17.80M$25.20M$19.53M
Total assets$32.12M$34.92M$18.26M$21.20M$29.73M$22.65M
Current assets$31.73M$34.50M$17.93M$20.88M$29.42M$22.34M
Total liabilities$28.58M$28.00M$8.43M$9.04M$11.06M$10.84M
Current liabilities$28.58M$28.00M$8.43M$9.04M$11.06M$10.84M
Total equity incl. NCI$3.54M$6.92M$9.83M$12.17M$18.67M$11.81M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$4.11M$4.24M$4.28M$4.60M$4.35M$4.18M

Cash flow

Allarity Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-06-302025-03-312024-12-31
Operating cash flow-$2.56M-$4.49M-$6.65M-$5.48M-$2.69MUnavailable
Capital expenditures$0$64.00K$8.00K$0$0Unavailable
Investing cash flow$0-$64.00K-$8.00K$0$0Unavailable
Financing cash flow$0$19.74M$2.07M-$2.56M$11.14MUnavailable
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Stock-based compensation$188.00K$160.00K$179.00K$164.00K$139.00KUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchases$0$262.00K$625.00K$2.56M$0Unavailable
Depreciation & amortizationUnavailableUnavailableUnavailable$12.00K$11.00KUnavailable

Derived

Allarity Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-06-302025-03-312024-12-31
Free cash flow-$2.56M-$4.56M-$6.66M-$5.48M-$2.69MUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailable-10752.0%-1698.8%UnavailableUnavailableUnavailable
FCF marginUnavailable-18228.0%-2081.6%UnavailableUnavailableUnavailable
SBC / revenueUnavailable640.0%55.9%UnavailableUnavailableUnavailable
Current ratio1.11x1.23x2.13x2.31x2.66x2.06x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailable-1930.9%UnavailableUnavailableUnavailable
R&D / revenueUnavailable5188.0%899.1%UnavailableUnavailableUnavailable
CapEx / revenueUnavailable256.0%2.5%UnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ALLR in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-30View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-15View SEC filing
10-Q · Filed 2025-05-09View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.